Oczyesa (Octreotide)

Octreotide mimics the natural hormone somatostatin and binds to somatostatin receptors, especially subtypes 2 and 5. This binding blocks the release of several hormones such as growth hormone, insulin, glucagon, and serotonin, and also reduces splanchnic blood flow, which underlies its therapeutic effects.

The specific dose and dosing schedule of Oczyesa are determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal clinical outcomes while minimizing adverse effects.

Octreotide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so breastfeeding is generally not recommended while receiving treatment unless the benefits outweigh the risks. Consultation with a healthcare provider is essential.

To request Oczyesa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Oczyesa (octreotide) is a short‑acting somatostatin analog, whereas some alternatives like lanreotide or long‑acting octreotide formulations provide extended dosing intervals. Choice depends on clinical needs, dosing convenience, and physician preference, with efficacy generally comparable across agents for approved indications.

Oczyesa should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Do not freeze the product. Before administration, inspect the solution for particulate matter or discoloration and use aseptic technique.

Oczyesa is supplied as an injectable solution for subcutaneous or intravenous injection. The route, injection site, and frequency are determined by the prescribing clinician. Proper aseptic technique and correct needle size are essential for safe administration.

Serious risks include pancreatitis, severe hypoglycemia, cardiac arrhythmias, anaphylactic reactions, and significant gallbladder disease. Patients should be monitored for abdominal pain, sudden changes in blood glucose, heart rhythm disturbances, or signs of allergic reaction, and seek immediate medical attention if they occur.

Oczyesa is contraindicated in patients with known hypersensitivity to octreotide or any component of the formulation. Caution is advised for individuals with severe cardiac disease, uncontrolled diabetes, or active gallbladder disease. The prescriber should evaluate each patient’s medical history before initiating therapy.